tetano
Editor, Senior Moderator
Nat Commun
. 2024 Jul 3;15(1):5589.
doi: 10.1038/s41467-024-49443-2. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective
Yuexiu Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Michelle Chamblee[SUP] #[/SUP][SUP] 1 [/SUP], Jiayu Xu[SUP] #[/SUP][SUP] 1 [/SUP], Panke Qu[SUP] 1 [/SUP], Mohamed M Shamseldin[SUP] 2 3 4 [/SUP], Sung J Yoo[SUP] 1 [/SUP], Jack Misny[SUP] 5 [/SUP], Ilada Thongpan[SUP] 5 [/SUP], Mahesh Kc[SUP] 5 [/SUP], Jesse M Hall[SUP] 2 [/SUP], Yash A Gupta[SUP] 2 [/SUP], John P Evans[SUP] 1 [/SUP], Mijia Lu[SUP] 1 [/SUP], Chengjin Ye[SUP] 6 [/SUP], Cheng Chih Hsu[SUP] 1 [/SUP], Xueya Liang[SUP] 1 [/SUP], Luis Martinez-Sobrido[SUP] 6 [/SUP], Jacob S Yount[SUP] 2 7 [/SUP], Prosper N Boyaka[SUP] 1 7 [/SUP], Shan-Lu Liu[SUP] 1 2 7 8 [/SUP], Purnima Dubey[SUP] 2 7 [/SUP], Mark E Peeples[SUP] 5 7 9 [/SUP], Jianrong Li[SUP] 10 11 [/SUP]
Affiliations
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1[SUP]-/-[/SUP] mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immunized female hamsters were protected from challenge with SARS-CoV-2 original WA1, B.1.617.2, and B.1.1.529 strains. The preexisting MeV and MuV immunity does not significantly interfere with the efficacy of TVC. Thus, the trivalent platform is a promising next-generation SARS-CoV-2 vaccine candidate.
. 2024 Jul 3;15(1):5589.
doi: 10.1038/s41467-024-49443-2. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective
Yuexiu Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Michelle Chamblee[SUP] #[/SUP][SUP] 1 [/SUP], Jiayu Xu[SUP] #[/SUP][SUP] 1 [/SUP], Panke Qu[SUP] 1 [/SUP], Mohamed M Shamseldin[SUP] 2 3 4 [/SUP], Sung J Yoo[SUP] 1 [/SUP], Jack Misny[SUP] 5 [/SUP], Ilada Thongpan[SUP] 5 [/SUP], Mahesh Kc[SUP] 5 [/SUP], Jesse M Hall[SUP] 2 [/SUP], Yash A Gupta[SUP] 2 [/SUP], John P Evans[SUP] 1 [/SUP], Mijia Lu[SUP] 1 [/SUP], Chengjin Ye[SUP] 6 [/SUP], Cheng Chih Hsu[SUP] 1 [/SUP], Xueya Liang[SUP] 1 [/SUP], Luis Martinez-Sobrido[SUP] 6 [/SUP], Jacob S Yount[SUP] 2 7 [/SUP], Prosper N Boyaka[SUP] 1 7 [/SUP], Shan-Lu Liu[SUP] 1 2 7 8 [/SUP], Purnima Dubey[SUP] 2 7 [/SUP], Mark E Peeples[SUP] 5 7 9 [/SUP], Jianrong Li[SUP] 10 11 [/SUP]
Affiliations
- PMID: 38961063
- DOI: 10.1038/s41467-024-49443-2
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1[SUP]-/-[/SUP] mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immunized female hamsters were protected from challenge with SARS-CoV-2 original WA1, B.1.617.2, and B.1.1.529 strains. The preexisting MeV and MuV immunity does not significantly interfere with the efficacy of TVC. Thus, the trivalent platform is a promising next-generation SARS-CoV-2 vaccine candidate.